SEC Stock Data Quick Answer Alector, Inc. reported Total Assets of $293.24 million for fiscal year 2025. Alector, Inc. Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $293.24M -37.4% 2024 $468.30M -24.7% 2023 $621.83M -21.1% 2022 $787.65M -3.3% 2021 $814.66M +66.9% 2020 $488.25M +15.7% 2019 $421.91M +36.8% 2018 $308.36M — Quarterly Total Assets Quarter … Read more
Quick Answer Alector, Inc. reported Diluted EPS of $1.39 per share (loss) for fiscal year 2025. Alector, Inc. Diluted EPS — Annual History Fiscal Year Diluted EPS YoY Change 2025 -$1.39 -13.0% 2024 -$1.23 +21.2% 2023 -$1.56 +3.7% 2022 -$1.62 -260.0% 2021 -$0.45 +81.6% 2020 -$2.45 — Quarterly Diluted EPS Quarter Ending Diluted EPS YoY … Read more
Quick Answer Alector, Inc. reported Net Income of -$142.93 million for fiscal year 2025. Alector, Inc. Net Income — Annual History Fiscal Year Net Income YoY Change 2025 -$142.93M -20.1% 2024 -$119.05M +8.7% 2023 -$130.39M +2.2% 2022 -$133.31M -267.0% 2021 -$36.33M +80.9% 2020 -$190.23M -80.5% 2019 -$105.39M -101.7% 2018 -$52.25M -60.9% 2017 -$32.48M — Quarterly … Read more
Quick Answer Alector, Inc. reported Revenue (ASC 606) of $21.05 million for fiscal year 2025. Alector, Inc. Revenue (ASC 606) — Annual History Fiscal Year Revenue (ASC 606) YoY Change 2025 $21.05M -79.1% 2024 $100.56M +3.6% 2023 $97.06M -27.4% 2022 $133.62M -35.5% 2021 $207.09M +881.5% 2020 $21.10M -0.6% 2019 $21.22M -22.9% 2018 $27.51M +857.8% 2017 … Read more
Quick Answer Alector, Inc. reported Total Revenue of $21.05 million for fiscal year 2025. Alector, Inc. Total Revenue — Annual History Fiscal Year Total Revenue YoY Change 2025 $21.05M -79.1% 2024 $100.56M +3.6% 2023 $97.06M -27.4% 2022 $133.62M -35.5% 2021 $207.09M +881.5% 2020 $21.10M -0.6% 2019 $21.22M -23.3% 2018 $27.68M +641.0% 2017 $3.73M — Quarterly … Read more
Quick Answer Alector, Inc. reported Total Revenue of $21.05 million for fiscal year 2025. Alector, Inc. — Key Financials by Year Metric 2025 2024 2023 2022 2021 2020 Total Revenue $21.05M-79.1% $100.56M+3.6% $97.06M-27.4% $133.62M-35.5% $207.09M+881.5% $21.10M-0.6% Revenue (ASC 606) $21.05M-79.1% $100.56M+3.6% $97.06M-27.4% $133.62M-35.5% $207.09M+881.5% $21.10M-0.6% Net Income -$142.93M-20.1% -$119.05M+8.7% -$130.39M+2.2% -$133.31M-267.0% -$36.33M+80.9% -$190.23M-80.5% Diluted EPS … Read more
Quick Answer Aldeyra Therapeutics, Inc. reported Shares Outstanding of 60.16 million shares for fiscal year 2025. Aldeyra Therapeutics, Inc. Shares Outstanding — Annual History Fiscal Year Shares Outstanding YoY Change 2025 60.16M +0.9% 2024 59.65M +0.8% 2023 59.20M +1.1% 2022 58.56M +0.8% 2021 58.08M +50.2% 2020 38.67M +34.9% 2019 28.66M +9.2% 2018 26.24M +37.1% 2017 … Read more
Quick Answer Aldeyra Therapeutics, Inc. reported Operating Income of -$35.27 million for fiscal year 2025. Aldeyra Therapeutics, Inc. Operating Income — Annual History Fiscal Year Operating Income YoY Change 2025 -$35.27M +41.3% 2024 -$60.12M -40.5% 2023 -$42.79M +31.7% 2022 -$62.68M -11.5% 2021 -$56.22M -54.4% 2020 -$36.42M +42.3% 2019 -$63.07M -58.9% 2018 -$39.70M -76.5% 2017 -$22.49M … Read more
Quick Answer Aldeyra Therapeutics, Inc. reported R&D Expense of $25.66 million for fiscal year 2025. Aldeyra Therapeutics, Inc. R&D Expense — Annual History Fiscal Year R&D Expense YoY Change 2025 $25.66M -46.8% 2024 $48.22M +63.7% 2023 $29.46M -37.7% 2022 $47.31M +5.3% 2021 $44.94M +82.1% 2020 $24.68M -44.4% 2019 $44.35M +48.7% 2018 $29.82M +82.9% 2017 $16.30M … Read more
Quick Answer Aldeyra Therapeutics, Inc. reported Stockholders Equity of $44.25 million for fiscal year 2025. Aldeyra Therapeutics, Inc. Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 $44.25M -37.7% 2024 $71.00M -40.7% 2023 $119.80M -20.7% 2022 $151.01M -26.6% 2021 $205.74M +245.7% 2020 $59.51M +23.8% 2019 $48.08M -44.5% 2018 $86.62M +118.7% 2017 $39.60M … Read more